Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
Toni K ChoueiriAmber C DonahueDavid A BraunBrian I RiniThomas PowlesJohn B A G HaanenJames M G LarkinXinmeng Jasmine MuJie PuRosemary E TeresiAlessandra di PietroPaul B RobbinsRobert J MotzerPublished in: Cancer discovery (2024)
Our findings provide novel insights into the different immunomodulatory mechanisms governing responses in patients treated with avelumab (PD-L1 inhibitor) + axitinib or sunitinib (both VEGF inhibitors), highlighting the contribution of tumor biology to the complexity of the roles and interactions of infiltrating immune cells in response to these treatment regimens. This article is featured in Selected Articles from This Issue, p. 384.